Therapy for Prevention and Relief of Hepatotoxic Reactions in Patients with Drug Resistant Tuberculosis
https://doi.org/10.58838/2075-1230-2025-103-2-13-21
Abstract
The objective: prevention and relief of hepatotoxic reactions to antituberculosis drugs in patients with infiltrative destructive pulmonary tuberculosis with multiple, pre-extensive and extensive drug resistance.
Subjects and Methods. Clinical and laboratory data of 160 patients receiving antituberculosis drugs and additionally morpholinium-methyl-triazolyl-thioacetate (Thiotriazolin) (TTZ Group) or Phosphogliv (Comparison Group (CG)) were comparatively analyzed.
Results. After 4 months, TTZ Group showed a decrease in frequency of toxic reactions to antituberculosis therapy, suppression of cytolysis and cholestasis syndrome as evidenced by decreased levels of ALT and AST enzymes, alkaline phosphatase, normalization of bilirubin levels and its fractions, and improved liver protein-synthetic function. In TTZ Group, normalization of the antioxidant defense system and free radical oxidation (FRO) was achieved, while in the comparison group, FRO rates did not show positive changes. Patients in TTZ Group showed more pronounced resorption of infiltration, healing of destruction sites, decrease in the frequency of bacterial excretion 4 months after the start of treatment versus Comparison Group.
About the Authors
L. A. Shovkun
Rostov State Medical University
Russian Federation
Russian Federation
Lyudmila A. Shovkun- Doctor of Medical Sciences, Professor, Head of Tuberculosis Department
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: + 7 (863) 250-42-00
D. A. Kudlay
I.M. Sechenov First Moscow State Medical University (Sechenov University); Immunology Research Institute by the Russian Federal Medical Biological Agency; Lomonosov Moscow State University
Russian Federation
Russian Federation
Dmitry A. Kudlay - Correspondent Member of RAS, Doctor of Medical Sciences, Professor of Pharmacology Department of Pharmacy Institute, Leading Researcher of Laboratory of Personalized Medicine and Molecular Immunology no. 71, Immunology Research Institute by the Russian Federal Medical Biological Agency, Professor of Department of Pharmacognosy and Industrial Pharmacy, Faculty of Fundamental Medicine, Lomonosov Moscow State University
8 Bd. 2, Trubetskaya St., Moscow, 119991
Phone: +7 (499) 248-05-53
E. D. Kampos
Rostov State Medical University
Russian Federation
Russian Federation
Elena D. Kampos - Candidate of Medical Sciences, Associate Professor of Tuberculosis Department
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: + 7 (863) 250-42-00
N. Yu. Nikolenko
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health
Russian Federation
Russian Federation
Nikolay Yu. Nikolenko - Candidate of Pharmacological Sciences, Leading Researcher of Scientific Clinical Department
10 Stromynka St., Moscow, 107014
Phone: + 7 (499) 268-00-05
T. A. Sevostyanova
Moscow Research and Clinical Center for Tuberculosis Control of the Moscow Government Department of Health; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatiana A. Sevostyanova - Doctor of Medical Sciences, Deputy Head of Pediatric Branch for Out-patient and Polyclinic Activities, Associate Professor of Phthisiology Department Clinical Medicine Institute, Pirogov Russian National Research Medical University, Russian Ministry of Health
10 Stromynka St., Moscow, 107014
Phone: + 7 (499) 268-00-05
I. M. Franchuk
Rostov State Medical University
Russian Federation
Russian Federation
Irina M. Franchuk - Candidate of Medical Sciences, Assistant of Tuberculosis Department
29 Nakhichevansky Lane, Rostov-on-Don, 344022
Phone: + 7 (863) 250-42-00
References
1. Belenichev I.F., Mazur I.A., Voloshin N.A.et al. Mechanism of anti-ischemic and antioxidant action of thiotriazoline. Novosti Meditsiny i Farmatsii. 2007, vol. 206, no. 2, pp. 67-68. (In Russ.)
2. Grechkanev G.O., Motovilova T.M., Garevskaya Yu.A. et al. Antioxidant therapy is the most important component of pathogenetic treatment of inflammatory diseases. Vrach, 2015, no. 3, pp. 54-59. (In Russ.)
3. Kinoschenko E.I., Nikonov V.V., Belaya I.E., Kolomiets V.I. Integrated approach to therapy of myocardial infarction combined with nonalcoholic fatty liver disease. Meditsina Neotlozhnykh Sostoyaniy, 2017, vol. 80, no. 1, pp. 47-60. (In Russ.)
4. Klinicheskie rekomendatsii Tuberkulez u vzroslykh. [Clinical guidelines on tuberculosis in adults]. ROF Publ., 2022.
5. Klinicheskiye rekomendatsii Lekarstvennyye porazheniya pecheni (LPP) u vzroslykh. [Guidelines on the management of drug-induced liver disorders (DILD) in adults]. RNMOT Publ., 2022.
6. Koltsov A.V., Tyrenko V.V. Cardioprotective effect of thiotriazoline in cancer patients. Russian Journal of Cardiology, 2023, vol. 1, no. 28, pp. 81-86. (In Russ.)
7. Lazebnik L.B., Golovanova E.V., Simanenkov V.I. et al. Possibilities of polytropic therapy with thiotriazoline in patients with non-alcoholic steatohepatosis and cardiovascular risk factors. The results of the TRIGON-1 observation program. Experimental and Clinical Gastroenterology, 2020, no. 8, pp. 10-18. (In Russ.)
8. Potupchik T., Veselova O., Evert L. et al. Use of the cytoprotector Thiotriazoline in cardiology practice. Vrach, 2015, no. 5, pp. 52-54. (In Russ.)
9. Romanova I.S., Kozhanova I.N., Gavrilenko L.N., Sachek M.M. Thiotriazoline in the integrated treatment of patients with ischemic heart disease. Kardiologiya i Kardiokhirurgiya, 2016, no. 3, pp. 36-43. (In Russ.)
10. Savchenko S.A., Filippov A.E. Proceedings of the Symposium Thiotriazoline: Cardioprotection from the Position of Evidence-Based Medicine within the framework of the Russian National Congress of Cardiologists. Russkiy Meditsinskiy Journal, 2017, no. 27, pp. 1638-1643. (In Russ.)
11. Topchiy N.V., Toporkov A.S. Possibilities of using Thiotriazoline as a metabolic therapy agent. Rossiyskiy Meditsinskiy Journal, 2015, no. 15, pp. 90-94. (In Russ.)
12. Khazanov A.I. Current problems of viral and alcoholic liver diseases. Rossiyskiy Journal Gastroenterologii, Gepatologii, Koloproktologii, 2002, no. 2, pp. 6-15. (In Russ.)
13. Shovkun L.A., Kudlay D.A., Nikolenko N.Yu., Kampos E.D., Kharseeva G.G. Specific features of the immune response to tuberculosis when drug susceptible and drug resistant strains of M. tuberculosis are detected. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 6, pp. 44-49. (In Russ.)
14. Shovkun L.A., Kudlay D.A., Nikolenko N.Yu., Kampos E.D. Pulmonary tuberculosis and free-radical oxidation. Tuberkulez i Sotsialno-Znachimye Zabolevaniya, 2019, no. 2, pp. 56-62. (In Russ.)
15. Shovkun L.A., Kudlay D.A., Nikolenko N.Yu., Kampos E.D. Characteristics of certain drugs with antioxidant activity and their use in tuberculosis treatment. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 4, pp. 58-64. (In Russ.)
16. Shovkun L.A., Kudlay D.A., Nikolenko N.Yu., Franchuk I.M. Accompanying therapy of patients with extensive drug-resistant (XDR) lung tuberculosis. European Respiratory Journal, 2018, vol. 52. 18, no. 62, suppl., pp. PA4747.
17. Shovkun L.A., Kudlay D.A., Nikolenko N. Yu., Campos E.D., Franchuk I.M. Prevention and mechanism of undesirable adverse reactions in patients with pulmonary tuberculosis with extensive drug-resistance (XDR) combined with type 2 diabetes. European Respiratory Journal, 2019, vol. 54. no. 63, suppl., pp. PA2970.
Review
For citations:
Shovkun L.A., Kudlay D.A., Kampos E.D., Nikolenko N.Yu., Sevostyanova T.A., Franchuk I.M. Therapy for Prevention and Relief of Hepatotoxic Reactions in Patients with Drug Resistant Tuberculosis. Tuberculosis and Lung Diseases. 2025;103(2):13-21. (In Russ.) https://doi.org/10.58838/2075-1230-2025-103-2-13-21
Views:
282
Email this article 